2012 Fiscal Year Final Research Report

Carbamylated erythropoietin ameliorates cyclosporine nephropathy withoutstimulating erythropoiesis

Research Project

Project/Area Number	22591806
Research Category	Grant-in-Aid for Scientific Research (C)
Allocation Type	Single-year Grants
Section	一般
Research Field	Urology
Research Institution	Osaka University
Principal Investigator	YAZAWA Koji 大阪大学, 医学系研究科, 助教 (40569109)
Co-Investigator(Kenkyū-buntansha)	TAKAHARA Shiro 大阪大学, 大学院・医学系研究科, 寄付講座教授 (70179547)
Project Period (FY)	2010 – 2012
Keywords	シクロスポリン腎症 / エリスロポイエチン / カルバミル化エリスロポイエチン
Research Abstract	The introduction of cyclosporine (CsA) has improved graft survival, but it causes nephropathy, which limits its clinical utility. To investigate the clinical applications of CEPO, we next evaluated the long-term therapeutic effect of CEPO using a CsA-induced nephropathy model. CsA caused renal dysfunction, while EPO/CEPO administration significantly improved renal function. EPO-treatment significantly increased Hb concentration, while CEPO-treatment neither enhanced nor reduced Hb concentration. These results suggest a new therapeutic approach using CEPO to protect kidneys from CsA-induced nephropathy.

(2 results)